Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Neuren Partner Acadia Signs Japan Distribution Deal for DAYBUE STIX

NEU: $22.74 -1.04% · MC: $2.9B

Neuren Pharmaceuticals’ partner Acadia has signed an exclusive agreement with KYORIN Pharmaceutical to commercialise DAYBUE STIX in Japan. Acadia anticipates a regulatory filing in 2027 and a potential launch in 2028, subject to approval; it had previously said it was seeking a distribution partner. Neuren is entitled to US$15 million after the first commercial sale, potential sales milestones of up to US$110 million and tiered royalties.

Source announcements: 2026-11-17 09:52 to 2026-11-17 09:52 Sydney time
Story updated 2026-11-17 10:35 Sydney time
SourcesAcadia enters DAYBUE STIX distribution agreement in Japan
Comments